$MRK Merck &amp; Foghorn entered a collab to use Foghorn’s proprietary Gene Traffic Control product platform to discover and develop #oncology assets against a transcription factor target.

Foghorn to receive an undisclosed upfront + up to $425M milestones.

https://t.co/fdKljVO8ga